What If You Could Kill Cancer Before It Even Starts?
A Dana-Farber trial used CAR-T therapy on patients who didn't have full-blown myeloma yet, and every single one responded with zero serious side effects. It could change when (and why) we deploy our most powerful cancer weapons.
Imagine getting a cancer treatment before you actually have cancer.
That's essentially what just happened at Dana-Farber Cancer Institute, and the results are turning heads across oncology. A small trial called CAR-PRISM used CAR-T cell therapy on patients who didn't have full-blown multiple myeloma yet, just a high-risk precursor condition. Every single patient responded. No one progressed to cancer. And the side effects? Practically nonexistent.
If that sounds like science fiction, you're not alone. But the data is real, and it could reshape how we think about cell therapy entirely.
The "Check Engine Light" Stage of Cancer
To understand why this matters, you need to know about smoldering multiple myeloma (SMM). Think of it like a check engine light on your car's dashboard. Something's wrong under the hood, but the car still drives fine. Your blood shows abnormal plasma cells and proteins that look a lot like myeloma, but you don't have the bone damage, kidney problems, or anemia that define the full disease.
For decades, doctors have handled SMM the same way most of us handle that dashboard light: watch it nervously and wait. The standard of care for high-risk SMM, even in 2026, is mostly active surveillance. Some patients get lenalidomide or daratumumab to delay progression, but many oncologists still prefer observation. The logic is simple: why expose someone to treatment side effects when they might not progress for years?
The problem? High-risk SMM patients aren't just sitting on a maybe. Some risk models show these patients face a roughly 40–50% chance of progressing to active myeloma within two years. That's not a check engine light. That's smoke coming from the hood.
20 for 20
The CAR-PRISM trial enrolled 20 patients with high-risk smoldering multiple myeloma and treated them with Carvykti (ciltacabtagene autoleucel), the BCMA-targeting CAR-T therapy from Johnson & Johnson and Legend Biotech. BCMA is a protein found on the surface of myeloma cells, and Carvykti is engineered to hunt it down.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The results were striking: all 20 patients hit MRD negativity within two months. MRD stands for minimal residual disease, and going "MRD negative" means doctors couldn't find any trace of the abnormal cells, even using ultra-sensitive testing (next-generation sequencing at a sensitivity of 10⁻⁶, for the nerds keeping score). That response held at a median follow-up of 15.3 months.
No patient progressed to active myeloma. No patient died. Ninety percent achieved a complete or stringent complete response.
And here's the kicker on safety: no grade 3 or higher cytokine release syndrome (the inflammatory overreaction that makes CAR-T scary), no serious neurotoxicity, and no high-grade side effects of any kind. For a therapy that routinely lands relapsed myeloma patients in the ICU, that safety profile in earlier-stage disease is remarkable.
Why Earlier Might Be Better
This isn't just about myeloma prevention. It's about a fundamental shift in when we deploy our most powerful cancer weapons.
CAR-T therapy was born in the last-chance saloon. Carvykti got its first FDA approval in February 2022 for patients who had already received at least four prior lines of therapy. Abecma (the other approved BCMA CAR-T, from Bristol Myers Squibb) arrived even earlier, in March 2021, also for heavily pretreated patients. These were drugs for people who had run out of options.
But the field has been creeping forward. In 2024, both products earned approvals for earlier use: Carvykti after just one prior line of therapy, Abecma after two. Trials in newly diagnosed myeloma are already underway at places like Cleveland Clinic.
The logic behind this migration is intuitive. When a patient has been through four or five rounds of treatment, their immune system is battered and their cancer has evolved resistance mechanisms. Sending in CAR-T cells at that point is like deploying firefighters after the building has mostly collapsed. But using them earlier, when tumor burden is lower and the immune system is healthier, could be a completely different game.
The CAR-PRISM data suggests that's exactly the case.
The "Very Important Question"
Experts are cautiously thrilled. Ecaterina Dumbrava of MD Anderson said the findings raise a "very important question" about whether early immune interception could "redefine treatment goals" and even prompted discussion of the C-word in oncology: cure.
Investigators on the trial described the results as the first report of this magnitude across the myeloma spectrum, noting that it "really shows the efficacy of CAR T-cells in earlier disease state."
But caution remains the dominant note. This was a single-center, early-phase study with just 20 patients. The follow-up, while encouraging, is still relatively short. And the broader expert community emphasizes that preventive CAR-T is investigational, not established practice. Plenty of promising small trials have fizzled in larger studies.
The Market Math Gets Interesting
If preventive CAR-T works at scale, it wouldn't just help patients; it would reshape the commercial landscape for cell therapy. Right now, the addressable market for CAR-T in myeloma is roughly the 36,000 new U.S. myeloma cases per year, minus whoever doesn't qualify for or access the treatment.
SMM is far more common than active myeloma. About 1 in 200 people over age 40 carry the condition. The high-risk subset is narrower, but it still represents a potentially significant new "pre-myeloma treatment segment" that doesn't exist today. Johnson & Johnson and Legend Biotech would love nothing more than to open that door.
The constraint, of course, is proving that the benefit justifies treating people who technically don't have cancer yet. Regulators and payers will want long-term survival data, not just MRD negativity at 15 months. And at roughly $465,000 per CAR-T infusion, the health economics conversation will be intense.
What Comes Next
The near-term consensus among experts: promising enough to keep pushing earlier, not yet enough to change clinical practice. Larger, multi-center trials will need to confirm these results. Longer follow-up will need to show that MRD negativity translates into actual prevention, not just delayed progression.
But something fundamental shifted with CAR-PRISM. For the first time, we have real clinical evidence that the most powerful cancer-killing technology in our arsenal might work best before cancer fully arrives. It's the difference between putting out a match and fighting a forest fire.
Twenty patients is a small number. But twenty for twenty? That's the kind of result that launches revolutions.
4 min read
The Gene Editor That Might Actually Delete Hepatitis B
Precision BioSciences just showed the first clinical evidence that a gene editor can destroy cccDNA, the hidden viral reservoir that makes hepatitis B nearly impossible to cure. If it holds up, 250 million patients worldwide could finally have a path off lifelong medication.
